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Phthalates are chemicals with known
endocrine-disrupting effects in rodents.
Animal studies suggest that prenatal exposure
to certain phthalates, specifically di-butyl
phthalate (DBP) and di-2-ethylhexyl phtha-
late (DEHP), induces adverse effects on the
male fetus that are distinct from effects
seen in adult animals. DBP, DEHP and its
metabolite mono-2-ethylhexyl phthalate
(mEHP), and di-isononyl phthalate (DiNP)
show antiandrogenic effects. They alter
Leydig cell differentiation and function and
thus diminish fetal testosterone production
(Borch et al. 2004, 2005; Fisher et al. 2003;
Foster et al. 2001; Gray et al. 2000). Animals
exposed in utero to DEHP show reduced
anogenital distance and nipple retention.
Additionally, a few animals have atrophic
testes, severely reduced sperm production,
cryptorchidism, or hypospadias (Jarfelt et al.
2005). These antiandrogenic actions of
phthalates have been documented in several
animal species (Kavlock et al. 2002a, 2002b).
Because phthalates are present ubiquitously
in the environment (e.g., polyvinyl chloride
ﬂooring, children’s toys, detergents, personal
care products) and in diet through food pro-
duction processes and packaging, humans are
continuously exposed. However, few popula-
tion studies on phthalate levels in humans have
been reported, and the signiﬁcance of exposure
for human health is still unknown. Metabolites
such as phthalate monoesters are particularly
high in urine samples of young women and
children with yet-unexplained differences
between social classes and ethnic groups (Silva
et al. 2004b). Recently, phthalates were also
detected in pooled breast milk samples from
American women (Calafat et al. 2004) and in
infant formula (Latini et al. 2004; Mortensen
et al. 2005; Petersen and Breindahl 2000; Shea
2003).
Adverse effects of fetal phthalate exposure
of humans may be detectable only in adult-
hood, and the development of early biomarkers
for adverse effects is thus imperative. Newborn
boys naturally exhibit a short activation of
the pituitary–gonadal axis at approximately
3 months of age (Andersson et al. 1998).
This feature can be applied diagnostically in
cases of gonadotropin deﬁciency or testicular
malfunction, because patients show a blunted
or even absent postnatal hormonal peak (Main
et al. 2000).
In this study we aimed to evaluate adverse
reproductive effects of exposure to phthalates
in newborn boys by correlating reproductive
hormone levels at 3 months of age to the
concentration of six phthalate monoesters in
breast milk, the major source of nutrition for
infants worldwide.
Materials and Methods
We obtained breast milk samples from a
joint prospective, longitudinal cohort study
performed 1997–2001 at Turku University
Hospital, Turku, Finland, and the National
University Hospital, Rigshospitalet, Copen-
hagen, Denmark. In this binational study we
aimed to establish contemporary prevalence
rates and geographic differences for cryptor-
chidism and hypospadias and evaluate risk fac-
tors for genital malformations (lifestyle and
exposure) by means of questionnaires and bio-
logic samples (blood samples of mother and
child, placentas and one breast milk sample
from each mother). The study was prospec-
tively planned by both research groups as a
joint venture in 1996. Recruitment, inclusion
criteria, and clinical examination of the chil-
dren—the identiﬁcation of cases with genital
malformations and controls—have been
described previously (Boisen et al. 2004). All
boys in these two cohort studies were examined
clinically at birth and again at 3 months of age
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Phthalates adversely affect the male reproductive system in animals. We investigated whether
phthalate monoester contamination of human breast milk had any inﬂuence on the postnatal surge
of reproductive hormones in newborn boys as a sign of testicular dysgenesis.
DESIGN: We obtained biologic samples from a prospective Danish–Finnish cohort study on cryp-
torchidism from 1997 to 2001. We analyzed individual breast milk samples collected as additive
aliquots 1–3 months postnatally (n = 130; 62 cryptorchid/68 healthy boys) for phthalate
monoesters [mono-methyl phthalate (mMP), mono-ethyl phthalate (mEP), mono-n-butyl phtha-
late (mBP), mono-benzyl phthalate (mBzP), mono-2-ethylhexyl phthalate (mEHP), mono-isononyl
phthalate (miNP)]. We analyzed serum samples (obtained in 74% of all boys) for gonadotropins,
sex-hormone binding globulin (SHBG), testosterone, and inhibin B.
RESULTS: All phthalate monoesters were found in breast milk with large variations [medians
(minimum–maximum)]: mMP 0.10 (< 0.01–5.53 µg/L), mEP 0.95 (0.07–41.4 µg/L), mBP 9.6
(0.6–10,900 µg/L), mBzP 1.2 (0.2–26 µg/L), mEHP 11 (1.5–1,410 µg/L), miNP 95 (27–469 µg/L).
Finnish breast milk had higher concentrations of mBP, mBzP, mEHP, and Danish breast milk had
higher values for miNP (p = 0.0001–0.056). No association was found between phthalate
monoester levels and cryptorchidism. However, mEP and mBP showed positive correlations with
SHBG (r = 0.323, p = 0.002 and r = 0.272, p = 0.01, respectively); mMP, mEP, and mBP with
LH:free testosterone ratio (r = 0.21–0.323, p = 0.002–0.044) and miNP with luteinizing hormone
(r = 0.243, p = 0.019). mBP was negatively correlated with free testosterone (r = –0.22, p = 0.033).
Other phthalate monoesters showed similar but nonsigniﬁcant tendencies.
CONCLUSIONS: Our data on reproductive hormone profiles and phthalate exposures in newborn
boys are in accordance with rodent data and suggest that human Leydig cell development and func-
tion may also be vulnerable to perinatal exposure to some phthalates. Our ﬁndings are also in line
with other recent human data showing incomplete virilization in infant boys exposed to phthalates
prenatally.
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[Online 7 September 2005]for signs of cryptorchidism. Standardization
of the clinical examination procedures was
achieved by repetitive workshops. Exposure
measurements in biologic samples were
prospectively planned to include persistent
and nonpersistent chemicals (European
Commission grant QLK4-CT-2001-00269).
From the total biobank of breast milk
samples, we included 65 samples from each
country for phthalate measurements (total n =
130), the number being determined by the
funding obtained for chemical analyses. These
samples represent 29/33 Danish/Finnish boys
with cryptorchidism (unilateral or bilateral)
either only at birth (25/8), or at birth and at
3 months of age (4/25). Thirty-six Danish and
32 Finnish control boys without cryptor-
chidism at any examination were included. In
Denmark, these control boys were selected
from the entire birth cohort at random (case-
cohort design). In Finland, control boys were
selected prospectively by a case–control design
in which boys with cryptorchidism were
matched at birth with controls for maternal
parity, smoking (yes/no), diabetes (yes/no),
gestational age (± 7 days), and date of birth
(± 14 days). This design was chosen in Finland
because of lack of sufﬁcient funding to follow
the entire cohort through infancy. We calcu-
lated weight for gestational age as percent
deviation from the expected mean (Marsál
et al. 1996), –22% being equivalent to –2
SDs. Three boys with cryptorchidism and
1 control were born small for gestational age
(< –22%); 5 boys with cryptorchidism and
3 controls were born prematurely (< 37 weeks
of gestation).
The study was conducted according to
the Helsinki II declaration (World Medical
Association 2004), after informed oral and
written consent of the parents. It was
approved by the ethical committees in both
countries (Joint Commission on Ethics of the
Turku University and the Turku University
Central Hospital, Turku, Finland; and the
Ethical Committees of Copenhagen and
Frederiksberg County, Cophenhagen, Den-
mark; and the Danish Data Protection
Agency, Cophenhagen, Denmark).
Each mother collected one breast milk
sample. Because we wished to assess the aver-
age exposure to phthalates during the time
period preceding the endogenous hormone
surge, this sample consisted of many small
aliquots collected over successive infant feed-
ings over several weeks up to a maximum
sample volume of 200 mL. For storage of the
breast milk sample, 250-mL Pyrex glass bot-
tles (Bibby Sterilin, Staffordshire, U.K.) with
Teﬂon-coated caps were given to the mothers
at birth. Mothers were instructed orally and
in writing to feed the baby first and then to
sample milk aliquots (hind milk), starting
from 1 month after birth. This start point was
chosen after discussion with the ethical com-
mittee for human subject studies to ensure
that breastfeeding had been well established
beforehand. Mothers were instructed to col-
lect samples into a glass container or porcelain
cup, avoiding the use of mechanical breast
pumps, if possible. Breast milk was frozen
consecutively in household freezers in a single
glass bottle as additive aliquots and delivered
frozen to the hospital at the 3-month exami-
nation. At the hospital, samples were stored at
–20°C until analysis. Only breast milk sam-
ples with total volumes > 50 mL were
included in the analyses to ensure that all
prospectively planned chemical analyses could
be performed. For 57 Danish mothers, infor-
mation on breast pump use was obtained at
sample delivery; 26 (46%) had used a pump
on one or more occasions during sample col-
lection for the study.
Venous nonfasting blood samples (4 mL)
were collected from the same boys whose
breast milk samples were used for analysis of
phthalate monoesters. Blood samples were
drawn on the day the breast milk sample was
delivered to the hospital. The boys were
median 3.01 (range, 2.43–4.08) months of
age. The success rate of venipuncture was 74%
(total n = 96; cryptorchid, n = 50; normal
boys, n = 46). After clotting, the blood sam-
ples were centrifuged, and the sera were sepa-
rated and stored at –20°C until analyzed.
All blood samples were analyzed as dupli-
cates and blinded for the technician at one
laboratory (Rigshospitalet, Denmark). Each
run contained blood samples of both cryp-
torchid and healthy boys from both Finland
and Denmark to minimize any effect of
interassay variation.
Serum follicle-stimulating hormone
(FSH), luteinizing hormone (LH), and sex
hormone–binding globulin (SHBG) were ana-
lyzed by time-resolved immunofluorometric
assays (Delﬁa, Wallac Inc., Turku, Finland).
Detection limits were 0.06 and 0.05 IU/L for
FSH and LH, respectively, and 0.23 nmol/L
for SHBG. The intra- and interassay coeffi-
cients of variation (CV) were < 5% in both
gonadotropin assays and < 6% in the SHBG
assay. Serum testosterone was measured by
radioimmunoassay (Coat-a-Count; Diagnostic
Products Corp., Los Angeles, CA, USA), with a
detection limit of 0.23 nmol/L; intra- and
interassay CVs were < 10%. Free testosterone
index was calculated from testosterone and
SHBG: [(testosterone × 100)/SHBG]. Serum
inhibin B was analyzed by a double antibody
enzyme-immunometric assay using a mono-
clonal antibody raised against the inhibin
βB-subunit in combination with labeled anti-
body raised against the α-subunit (Groome
et al. 1996). The detection limit was 20 pg/mL,
and intra- and interassay CVs were < 15% and
< 18%, respectively. Ratios between hormones
were calculated by simple division: LH/testos-
terone, LH/free testosterone, FSH/inhibin B.
For determination of phthalate mono-
esters, breast milk samples were thawed and
placed in a water bath at 37°C to get a homo-
geneous sample without a separate fat layer. An
aliquot of 3 mL was removed for liquid extrac-
tion using a mixture of ethyl acetate and cyclo-
hexane (95:5) followed by a two-step solid
phase extraction as described in detail previ-
ously (Mortensen et al. 2005). Determination
of phthalate monoesters was accomplished
by high-pressure liquid chromatography
(Surveyor; Thermo Finnigan, San Jose, CA,
USA) with a Betasil Phenyl column (100 ×
2.1 mm × 3 µm) (Thermo Hypersil-Keystone,
Thermo Finnigan). Column temperature
was 25°C, injection volume was 20 µL, and
flow rate was 350 µL/min. A Finnigan TSQ
Quantum Ultra triple quadrupole mass spec-
trometer in combination with the Xcalibur
software program was used for detection and
quantitation (Thermo Electron Corporation,
San Jose, CA, USA). The instrument was run
in negative mode using the electro spray source
(ESI). Detection limits were in the range
of 0.01 to 0.5 µg/L. Recoveries at two different
levels ranging from 2 to 120 µg/L were
included using different milk samples and the
CV (percent) was calculated from measure-
ments of real duplicate determinations during
the project period. Recovery was 93–104%
and method variation was 5–15%. All analyses
were carried out blinded with regard to the
child’s clinical examination or serum hormone
concentration of reproductive hormones.
Statistics
Population characteristics are given as medians
and percentiles (2.5th, 97.5th). Differences
between boys with and without cryptor-
chidism were analyzed by Mann-Whitney
U-test (Table 1). Six breast milk samples with
undetectable values for mono-methyl phtha-
late (mMP) were assigned the limit of detec-
tion (LOD) value for mMP (0.01 µg/L)
before statistical analysis. Estimates of daily
exposure levels (micrograms per day) were cal-
culated by the following equation: phthalate
monoester concentration in breast milk
(micrograms per liter) × infant weight at
3 months (kilograms) × average milk con-
sumption (0.120 L/kg/day). To calculate the
exposure as micrograms per kilograms per day,
phthalate concentration (micrograms per liter)
was multiplied by 0.120 L.
We tested differences in phthalate mono-
ester concentration in breast milk and daily
exposures between countries, as well as phtha-
late monoester concentration in breast milk
between boys with and without cryptor-
chidism, by Mann-Whitney U-test. We tested
associations between phthalate monoesters by
Spearman correlations.
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hormone levels and phthalate monoesters, we
used a multiple regression analysis with log-
transformed data. Potential confounders (ges-
tational age, weight for gestational age, parity,
smoking, diabetes, country of origin) were
investigated, and finally only country of ori-
gin was entered as confounder.
We then tested associations between six
phthalate monoesters and seven reproductive
hormones as well as three hormonal ratios with
partial Spearman correlations while adjusting
for country differences. Because of the small
sample size, we obtained p-values for the exact
distributions by Monte Carlo permutation.
Results
Table 1 describes the study population char-
acteristics for boys with and without cryp-
torchidism separately, which do not show
significant differences for maternal or infant
parameters.
Concentrations of phthalate monoesters
showed large interindividual variations, with
single samples being extreme compared with
the country median (Table 2). Except for
mMP, all six phthalates were detectable in all
breast milk samples; mMP could not be found
in 2 of 65 (3%) Danish and in 4 of 65 (6%)
Finnish samples. Mono-isononyl phthalate
(miNP) showed the highest concentration of
all phthalate monoesters. There was a signiﬁ-
cant difference between Denmark and Finland
for four phthalate monoesters (Figure 1).
Finland showed higher values for mono-n-
butyl phthalate (mBP) (p = 0.0001), mono-
benzyl phthalate (mBzP) (p = 0.0001), and
mEHP (p = 0.001), but lower values for miNP
(p = 0.056). Individual phthalate monoester
concentrations were positively correlated to
each other (r = 0.24–0.43, p = 0.0001), except
for miNP, which was not correlated to any
other phthalate.
There was no significant difference (p =
0.440–0.823) between children with or with-
out cryptorchidism with regard to any phtha-
late monoester concentration in breast milk, if
analyzed either separately for each country
(data not shown) or together. Median concen-
trations (cases vs. controls) were 0.094 versus
0.103 µg/L mMP; 0.898 versus 0.976 µg/L
for mono-ethyl phthalate (mEP); 10.25 versus
9.09 µg/L for mBP; 1.25 versus 1.20 µg/L for
mBzP; 10.55 versus 10.51 µg/L for mEHP;
and 98.52 versus 91.75 µg/L for miNP.
Information on the use of mechanical
breast pumps was available only for the Danish
samples, in which signiﬁcantly higher mEP and
mBP levels were observed when breast pumps
were used (p = 0.001 and p = 0.02, respec-
tively). In the laboratory, we tested whether
incubation of breast milk at 37°C for 2 hr in a
commonly used polycarbonate breast pump
influenced the level of phthalate monoesters
measured. No increase or decrease in any of the
six phthalate monoesters could be observed.
Phthalate monoesters were associated with
hormones related to Leydig cell function. Both
mEP and mBP showed signiﬁcant positive cor-
relations with SHBG (Table 3). A 10-fold
increase in mEP/mBP raised serum SHBG
levels by 15% (3–28%) and 8% (–1 to 18%),
respectively. Both mBzP and miNP showed the
same tendency but did not reach statistical sig-
niﬁcance. The LH:free testosterone ratio was
significantly positively correlated to mMP,
mEP, and mBP, with similar, nonsigniﬁcant
tendencies for mEHP (p < 0.095) and miNP
(p < 0.099). A 10-fold increase in mMP, mEP,
and mBP concentrations raised the LH:free
testosterone ratio by mean 19% (–3 to 46%),
26% (–1 to 60%), and 18% (–2 to 44%),
respectively. Correlations between LH:testos-
terone ratio and mMP, mEP, mBP, and
mEHP showed tendencies (p < 0.10) in the
same direction (positive association), but none
reached statistical signiﬁcance. Free testosterone
was significantly negatively correlated with
mBP, with a change of –15% (–29 to +1%)
over a 10-fold increase of mBP. Both mEP and
mEHP showed similar, nonsigniﬁcant tenden-
cies. Examples of regression plots for mEP are
shown in Figure 2. miNP dose dependently
increased serum LH and showed a tendency
toward increasing total testosterone. A 10-fold
increase of miNP raised LH levels by 97%
(23–214%). We found similar correlations
between phthalate monoester concentrations in
breast milk and serum levels of reproductive
hormones when analyzing only the group of
boys without cryptorchidism from both coun-
tries (Table 4).
Findings concerning the two markers of
Sertoli cell function (FSH, inhibin B) were
subtle (Table 3). There was a tendency toward
an increase in inhibin B with increasing con-
centration of mBzP and mEHP, which did not
reach statistical significance. All phthalate
monoesters showed a negative correlation to
the FSH:inhibin B ratio, which reached statis-
tical signiﬁcance only for mEHP. In the con-
trol group, no associations were seen between
markers of Sertoli cell function and phthalate
monoester concentration in breast milk
(Table 4). Parity, maternal smoking during
pregnancy, diabetes, gestational age, and
weight for gestational age were not signiﬁcant
confounders for the association between phtha-
late monoesters and reproductive hormones.
Estimates of average infant exposure to
phthalate monoesters (micrograms per day
and micrograms per kilogram per day) are
given in Table 5. The lowest exposure was
seen for mMP, mEP, and mBzP, and the
highest was seen for mBP, mEHP, and miNP.
There were signiﬁcant country differences in
daily intake of mBP and mBzP.
Discussion
We found subtle but signiﬁcant dose-depen-
dent associations between neonatal exposure
to phthalate monoesters in breast milk and
Main et al.
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Table 1. Study population characteristics [median (2.5th–97.5th percentile)] and p-value for differences
between boys with and without cryptorchidism (Mann-Whitney U-test).
Boys with cryptorchidism Healthy boys
Characteristic (n = 62) (n = 68) p-Value
No. (Denmark, Finland) 29, 33 36, 32 0.484
Maternal age (years) 29.7 (21.8–39.5) 29.3 (22.2–40.5) 0.415
Maternal diabetes (yes, no) 5, 57 1, 67 0.075
Maternal smoking (yes, no) 13, 49 13, 55 0.793
Parity
1 37 47 0.230
21 4 1 3
≥ 31 1 8
Gestational age (days) 280 (236–296) 282 (227–296) 0.089
Weight for gestational age (%) 0.82 (–30.2 to 28.9) 0.15 (–22.4 to 33.7) 0.795
Birth weight (kg) 3.60 (1.99–4.76) 3.68 (2.78–4.81) 0.598
Birth length (cm) 52 (43–59) 52 (48–57) 0.284
Placenta weight (g) 550 (280–942) 600 (350–1,228) 0.164
Weight 3 months (kg) 6.55 (4.88–8.25) 6.58 (5.31–8.51) 0.804
Length 3 months (cm) 63 (60–67) 63 (57–67) 0.431
Table 2. Median concentration [range (µg/L)] of six phthalate monoesters in human breast milk samples
1997–2001, collected as additive aliquots from 1 to 3 months postnatally.
Denmark Finland LOD Detection rate
Phthalate (n = 65) (n = 65) p-Value (µg/L) (%)
mMP 0.10 (< 0.01–5.53) 0.09 (< 0.01–0.37) 0.355 0.01 95
mEP 0.93 (0.07–33.6) 0.97 (0.25–41.4) 0.976 0.01 100
mBP 4.3 (0.6–10,900) 12 (2.4–123) 0.0001 0.05 100
mBzP 0.9 (0.2–14) 1.3 (0.4–26) 0.0001 0.05 100
mEHP 9.5 (1.5–191) 13 (4.0–1,410) 0.001 0.10 100
miNP 101 (27–469) 89 (28–230) 0.056 0.50 100
Country differences were tested by Mann-Whitney U-test.levels of reproductive hormones in boys at
3 months of age. The most consistent ﬁndings
were that higher phthalate monoester concen-
trations in mothers’ breast milk were linked to
higher serum SHBG levels and LH:free testos-
terone ratios. For mBP, higher exposure was
also associated with lower free serum testos-
terone levels. Similar antiandrogen effects have
been observed previously in newborn rodents
exposed perinatally to phthalate diesters and
monoesters (Albro et al. 1989; Foster et al.
2001; Gray et al. 2000; Jarfelt et al. 2005; Li
et al. 1998). Average exposure of infants from
breast milk was lower than doses used in ani-
mal exposure studies. However, exposure
through lactation is only one of many poten-
tial exposure routes, and children are exposed
to many phthalates simultaneously. Estimates
for the tolerable daily intake (TDI; milligrams
per kilogram per day) for phthalate diesters in
humans are currently 0.05 for mMP, mBzP,
and mEHP; 0.2 for di-ethyl phthalate (DEP);
0.1 for DBP; and 0.15 for DiNP (European
Commission 2004; Kavlock et al. 2002a,
2002b; Petersen and Breindahl 2000). A
direct comparison of exposure to monoesters
to these values is not possible. The magnitude
of the average exposure levels appears to be
below currently established TDIs for the
diesters. However, individual children can
exceed these limits, especially for the metabo-
lites of DBP and DEHP.
Our study showed that the absolute con-
centration of phthalate monoesters such as
mBP, mBzP, and mEHP in breast milk dif-
fered between countries despite close geo-
graphic vicinity and comparable lifestyles.
Thus, values reported here may not be directly
applicable to other populations. Another large
population survey has likewise shown that age,
sex, and ethnicity affect concentrations of
phthalate monoesters measured in urine (Silva
et al. 2004b). In this study we also demon-
strated that very little is known about individ-
ual sources of phthalate exposure and exposure
variation and even less about potential differ-
ences in metabolism between people. A con-
siderable intraindividual variation in urinary
phthalate metabolite excretion has been
demonstrated (Hauser et al. 2004). Only one
previous study measured the same phthalate
metabolites as in our study in three pooled
samples of breast milk from American women.
That study reported lower levels than observed
here or previously in Danish control women
(Calafat et al. 2004; Mortensen et al. 2005).
Our LOD values were considerably lower
than those in the American study, and we
assessed the average phthalate exposure from 1
to 3 months postnatally, which may explain
part of the differences. Our study showed, in
agreement with the American report, that the
metabolites of longer-chain phthalates such as
mEHP and miNP, in particular, are found in
milk samples, whereas the shorter-chain com-
pounds such as mEP are more prevalent in
urine and serum in the glucuronidated form
(Silva et al. 2004a). This ﬁnding corresponds
well to the increasing fat solubility of longer-
chain phthalates, which may facilitate their
higher segregation into milk. The detection
rate of phthalate metabolites in human breast
milk was 95% for mMP and 100% for all
others including miNP, higher than in most
other human matrices studied such as urine,
serum, amniotic ﬂuid, and saliva (Duty et al.
2005, Hauser et al. 2004; Silva et al. 2004a,
2004b, 2004c).
Breast milk samples can potentially be con-
taminated with phthalate diesters during col-
lection and storage. It is generally accepted that
phosphoric acid should be added immediately
Phthalate monoesters and infant hormones
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Table 3. Spearman correlations between concentrations of phthalate monoesters (µg/L) in human breast
milk and reproductive hormones in serum of boys 3 months of age with and without cryptorchidism (n = 96).
Hormone mMP mEP mBP mBzP mEHP miNP
Leydig cell function
SHBG (nmol/L) 0.076 0.323 0.272 0.188 0.080 0.187
p-Value 0.475 0.002 0.01 0.074 0.452 0.076
LH (IU/L) 0.159 0.185 0.076 0.049 0.001 0.243
p-Value 0.128 0.075 0.469 0.643 0.994 0.019
Testosterone (nmol/L) 0.009 –0.010 –0.040 0.115 –0.09 0.184
p-Value 0.929 0.927 0.705 0.271 0.392 0.078
Free testosterone –0.065 –0.191 –0.220 –0.007 –0.169 0.070
p-Value 0.539 0.068 0.033 0.951 0.107 0.510
LH:testosterone ratio 0.174 0.189 0.200 –0.007 0.180 0.092
p-Value 0.098 0.072 0.056 0.946 0.087 0.384
LH:free testosterone ratio 0.210 0.323 0.282 0.060 0.175 0.174
p-Value 0.044 0.002 0.006 0.570 0.095 0.099
Sertoli cell function
FSH (IU/L) 0.041 0.050 –0.083 0.045 –0.122 –0.043
p-Value 0.696 0.633 0.417 0.668 0.240 0.681
Inhibin B (pg/mL) 0.101 0.116 0.055 0.181 0.185 –0.004
p-Value 0.333 0.267 0.596 0.083 0.075 0.972
FSH:Inhibin B ratio –0.006 –0.027 –0.132 –0.049 –0.204 –0.058
p-Value 0.951 0.796 0.202 0.641 0.050 0.584
p-Values are not adjusted for multiple testing.
Figure 1. Concentration of six phthalate monoesters (µg/L) in human breast milk samples from Denmark
(n = 65) and Finland (n = 65), 1997–2001, collected between 1 and 3 months postnatally as additive aliquots.
Data are given as percentile distribution. (A) mMP, (B) mEP, (C) mBP, (D) mBzP, (E) mEHP, (F) miNP.
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Denmark
Finlandto serum samples to inhibit esterase activity.
We did not find any difference in phthalate
monoester concentrations after thawing of the
breast milk samples with and without the addi-
tion of phosphoric acid (Mortensen et al.
2005), showing that no contamination
occurred during the analytic handling of the
sample. However, another study reported a
rapid increase in monoesters after spiking of
defrosted breast milk samples with DEHP,
DBP, and benzylbutylphthalate if no phos-
phoric acid was added (Calafat et al. 2004).
Thus, we cannot exclude that contamination
may occur during collection at home (e.g.,
from air particles, dust, locally applied cosmet-
ics, or containers such as breast pumps), aug-
menting the concentration of monoesters
before the samples reach the hospital. We
decided against the addition of phosphoric acid
because samples were collected at home as
additive aliquots of unknown volume. Open
handling of phosphoric acid was not consid-
ered safe. In addition, the ﬁnal volume of the
sample delivered at the 3-month examination
could not be predicted, which inhibited the
precise calculation of the necessary volume of
phosphoric acid. However, if contamination of
breast milk samples had occurred at random in
our study, our chances of ﬁnding associations
with endogenous hormones would have been
considerably weakened. Thus, we believe that
our ﬁndings of associations between phthalate
monoester levels and reproductive hormones
may be potentially underestimated, not the
reverse. However, the absolute concentrations
reported here must be interpreted with caution
and may not be applicable to other study
settings.
In rodents, secondary-step metabolites of
DEHP such as mono(2-ethyl-5-hydroxyhexyl)
phthalate (mEHHP) and mono(2-ethyl-5-oxy-
hexyl) phthalate (mEOHP) are suspected to be
more toxic than DEHP or mEHP itself (Latini
2005). There are ﬁrst reports on measurement
of these metabolites in human matrices such as
urine, serum, and saliva. However, these reports
are seriously hampered by lack of analytic sen-
sitivity, with the majority of samples being
below the LOD or quantiﬁcation (Calafat et al.
2004; Kato et al. 2004; Silva et al. 2005).
Further research into the analytic method for
determination of oxidative metabolites in breast
milk and other matrices, as well as studies into
their toxicity for humans, are urgently needed.
To our knowledge, this is the ﬁrst report
showing an association between phthalate
exposure and reproductive hormones in boys.
We are aware of problems in connection with
conducting multiple analyses. Additional
analysis of the data including only healthy
boys without cryptorchidism showed com-
parable findings with the total group, thus
strengthening our conclusion of a subtle effect
on endogenous hormone levels related to
Leydig cell function. We did not find any
correlation of phthalate exposure with cryp-
torchidism, which disagrees with rodent stud-
ies (Imajima et al. 2001; Jarfelt et al. 2005;
Kavlock et al. 2002a, 2002b). However, we
did not find significant differences in birth
weight, weight for gestational age, or gesta-
tional age between boys with and without
cryptorchidism, which is in contrast to our
ﬁndings in the total baby cohort from which
this data set is derived (Boisen et al. 2004).
This indicates that our study groups may
be too small to detect subtle changes related
to the presence or absence of congenital cryp-
torchidism. As testicular descent occurs pre-
natally, our postnatal exposure assessment
during lactation may have missed the critical
window for development. We have no data
currently on how milk contamination with
phthalate metabolites compares with prenatal
exposure through placenta and amniotic
fluid. Increased SHBG is an indirect sign of
reduced androgen activity (Belgorosky and
Rivarola 1985). Elevated LH levels, together
with decreased free testosterone and elevated
LH:free testosterone ratio, are consistent with
an adverse effect on Leydig cell function lead-
ing to a reduced biologic androgen effect.
Physiologically, there is negative feedback
between testosterone levels in serum and pitu-
itary LH secretion. In addition, miNP was
associated with serum LH levels. This ﬁnding
is of particular concern, as DiNP today has
replaced DEHP in many applications such as
food packaging, ﬂexible plastic toys, and ﬂoor-
ing, and the exposure levels found in our
study were the highest among all six phthalate
monoesters analyzed. Our ﬁndings concerning
mEHP, a phthalate with a higher reproductive
toxicity in animal experiments than its parent
compound, DEHP, also showed a tendency
toward an antiandrogenic effect, which did
not reach statistical signiﬁcance. This may be
related to the limited number of samples in
our study, the extreme variation of individual
exposure levels, or species differences.
Interestingly, in an independent, parallel
American study of another mother–child
cohort, women with highest excretion of
mEP, mBP, mBzP, and mono-isobutyl phtha-
late (miBP) in urine during pregnancy gave
birth to boys who were less virilized, as judged
from smaller than expected measurements
of anogenital distance. We did not measure
anogenital distance in our cohort. However,
our observations on the associations between
mBP and mEP and markers of Leydig cell
function, in particular, are consistent with the
American study (Swan et al. 2005) in terms of
an antiandrogenic effect of phthalate exposure
in infants boys, assessed by two different bio-
markers. We also found an effect of mEP on
SHBG levels and on the ratio between LH
and free testosterone, whereas rodent studies
did not show any toxicity of its parent com-
pound, DEP (Gray et al. 2000). Because mEP
was also one of four phthalate metabolites
affecting anogenital distance in the American
baby study, these observations may indicate a
species difference in vulnerability that will
have to be studied thoroughly in the future.
We observed hormonal changes indicating
an effect on Sertoli cells—an increase in inhibin
B—which we did not expect and therefore
Main et al.
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Figure 2. Regression plots of mEP levels (µg/L) in human breast milk and serum hormonal levels in boys 3 months of age (n = 96). The x- and y-axes for mEP, free
testosterone, SHBG, and LH:free testosterone ratio are logarithmic. The slopes (confidence interval) of the regression lines are (A) free testosterone, 0.86
(0.69–1.06); (B) LH:free testosterone ratio, 1.26 (0.99–1.60); and (C) SHBG 1.15 (1.03–1.28). Example of interpretation: A 10-fold increase in mEP, for example, from 1
to 10 µg/L, is associated with a 15% increase in SHBG from 140.5 to 161.3 nmol/L.
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Denmark
Finlandconsidered a random finding. However, a
recent report found a similar, equally weak,
effect in adult men (Duty et al. 2005). We can-
not yet explain this observation and, unfortu-
nately, inhibin B levels have not been measured
in animal experiments. However, histologic
studies of rodent testes exposed pre- and perina-
tally show vacuolization of Sertoli cells (Borch
et al. 2004, 2005) and apoptosis of spermato-
genic cells in cultures of mouse seminiferous
tubules (Suominen et al. 2003).
Although the hormonal changes in the
boys were linked to phthalate monoester levels
in breast milk, we cannot exclude that fetal
exposure may be a contributing factor to
altered postnatal hormone levels. Levels of
phthalate monoesters in breast milk may be a
proxy of general maternal exposure: the
women with high levels of phthalate mono-
esters in milk may also be among those with
highest exposures during pregnancy. Phthalates
can cross the placenta; DEHP and mEHP have
been detected in maternal and cord blood
(Latini et al. 2003) and their metabolites were
found in amniotic fluid (Silva et al. 2004c).
Sources of phthalate exposures in women can
be inhalation (Adibi et al. 2003), contamina-
tion via building materials and furniture, use of
consumer products including cosmetics (Koo
and Lee 2004), and food items (Anderson et al.
2001). Thus, exposure to some phthalates such
as DEHP and DiNP is likely to be constant
rather than episodic, whereas others such as
DMP and DEP, through their presence in cos-
metics, are more inﬂuenced by personal habits.
The observed effects on endocrine hormone
levels could therefore be late effects of fetal
exposure or additive fetal and neonatal expo-
sure through the mother, or exposure to a
home environment generally rich in phthalates
during pregnancy and infancy.
We observed a significant difference in
mEP and mBP levels depending on whether
breast milk was sampled with or without use
of a breast pump. This observation is unlikely
to have any link to the observed associations
between phthalate monoester levels in breast
milk and infant hormone levels. Danish and
Finnish mothers have several months of
maternity leave, and breast pumps are not
used regularly for infant feeding. Furthermore,
in our laboratory we could not observe any
leaching of phthalates from a commonly used
mechanical breast pump into breast milk.
Thus, it remains to be verified whether our
observed difference in mEP and mBP was a
true effect of breast pump use or a chance
ﬁnding.
Individuals will often be exposed to a mix-
ture of endocrine-disrupting chemicals—for
example, phthalates in cosmetics usually co-
exist with parabens, which also act as endocrine
disruptors. In situations where mixtures of
agents even in minute concentrations con-
tribute to the adverse effects (Silva et al. 2002),
causal relationships are extremely difficult
to establish. We cannot rule out that our ﬁnd-
ings could be due to one or multiple unknown
factors, the presence of which is associated
with the use of phthalates. Breast feeding has
numerous beneﬁts for infant nutrition and for
establishing an ideal mother–child relationship.
We do not believe that our data should be
taken to argue against breast-feeding, because
effects on reproductive hormones were subtle.
In addition, phthalates have also been found
in other major nutrition sources for infants
(Latini et al. 2004; Mortensen et al. 2005;
Petersen and Breindahl 2000; Shea 2003).
In conclusion, our findings support the
hypothesis that the human testis may be
vulnerable to phthalate exposure during devel-
opment. Before any regulatory action is con-
sidered, further studies on health effects of
phthalate esters and their metabolites in
humans are urgently needed. These studies
should be aimed specifically at verifying or
refuting our findings. In this respect, breast
milk samples may be a valuable biologic matrix
for assessing long-term average exposure,
not only to persistent toxicants but also to
endocrine disrupters with a short half-life such
as phthalates. In addition, the postnatal activa-
tion of the pituitary–gonadal axis in infants
appears to be a valuable biomarker for early
detection of endocrine disruption in humans.
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